Literature DB >> 11560984

The Indian scene.

R Chopra1.   

Abstract

Breast cancer is the second most common cancer among women in India, after cancer of the cervix uteri. Presently, 75,000 new cases occur in Indian women every year. This figure must be viewed against the backdrop that the national cancer registry and the hospital-based tumor registries hardly sample 3% of the total population. Locally advanced breast cancer constitutes more than 50% to 70% of patients presenting for treatment. The management of the patients varies according to the hospital the patient seeks treatment from. In this vast country, hospitals vary from peripheral hospitals with basic facilities to the specialized institutions in the metropolitan centers with all specialists, medical oncologists, radiation oncologists, surgical oncologists, and supporting facilities. In the peripheral hospitals, the treatment is invariably a radical mastectomy with or without radiotherapy. In the metropolitan areas and in specialized cancer institutions, management mirrors international recommendations with brachiocephalic trunk or modified radical mastectomy, radiation therapy, and chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11560984

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  40 in total

1.  Breast Cancer in Low and Middle Income Countries: How Can Guidelines Best Be Disseminated and Implemented?

Authors:  Benjamin O Anderson; Vivien D Tsu
Journal:  Breast Care (Basel)       Date:  2008-02-22       Impact factor: 2.860

2.  Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer.

Authors:  Taher A Al-Tweigeri; Dahish S Ajarim; Adher A Alsayed; Mohamed M Rahal; Mohamed O Alshabanah; Asma M Tulbah; Osama A Al-Malik; Doha M Fatani; Gamal A El-Husseiny; Naser B Elkum; Adnan A Ezzat
Journal:  Med Oncol       Date:  2009-06-13       Impact factor: 3.064

3.  Usefulness of serum CA 15.3 and histopathological prognostic indices in breast cancer.

Authors:  R Nalini; C R Wilma Delphine Silvia; Purnima M Makhija; Sheila Uthappa
Journal:  Indian J Clin Biochem       Date:  2005-01

4.  Hormone Receptors, Her-2/Neu and Chromosomal Aberrations in Breast Cancer.

Authors:  V Dutta; G S Chopra; K Sahai; S K Nema
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 5.  Challenges to the early diagnosis and treatment of breast cancer in developing countries.

Authors:  Karla Unger-Saldaña
Journal:  World J Clin Oncol       Date:  2014-08-10

6.  Lay perceptions of breast cancer in Western Kenya.

Authors:  Violet Naanyu; Chite Fredrick Asirwa; Juddy Wachira; Naftali Busakhala; Job Kisuya; Grieven Otieno; Alfred Keter; Anne Mwangi; Orango Elkanah Omenge; Thomas Inui
Journal:  World J Clin Oncol       Date:  2015-10-10

7.  Promoter Hypermethylation in Tumor Suppressing Genes p16 and FHIT and Their Relationship with Estrogen Receptor and Progesterone Receptor Status in Breast Cancer Patients from Northern India.

Authors:  Mohammad Raish; Varinderpal S Dhillon; Arif Ahmad; Mushtaq Ahmad Ansari; Shahid Mudassar; Mohammad Shahid; Vineeta Batra; Pawan Gupta; Bhudev Chandra Das; Nk Shukla; Syed Akhtar Husain
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

8.  Posttraumatic growth among cancer patients in India.

Authors:  Avinash Thombre; Allen C Sherman; Stephanie Simonton
Journal:  J Behav Med       Date:  2009-10-15

Review 9.  Breast cancer issues in developing countries: an overview of the Breast Health Global Initiative.

Authors:  Benjamin O Anderson; Raimund Jakesz
Journal:  World J Surg       Date:  2008-12       Impact factor: 3.352

10.  Wortmannin induces MCF-7 breast cancer cell death via the apoptotic pathway, involving chromatin condensation, generation of reactive oxygen species, and membrane blebbing.

Authors:  Rozina Akter; Md Zakir Hossain; Maurice G Kleve; Michael A Gealt
Journal:  Breast Cancer (Dove Med Press)       Date:  2012-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.